January 2024 in “Circulation” This commentary explores the role of PCSK9 as a target for drug development, underscoring that individuals with PCSK9 loss-of-function mutations experience significantly lowered LDL cholesterol levels and reduced coronary events, suggesting that full inactivation of PCSK9 is effective and safe.
This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
February 2022 in “International journal of KIU” This review discusses genetic susceptibility and dietary factors influencing COVID-19 severity and summarizes the genetic variants linked to infection outcomes, but it reports no new clinical results.
391 citations
,
September 2015 in “Journal of Clinical Lipidology” This document extends previous recommendations by the National Lipid Association for managing dyslipidemia, focusing on lifestyle therapies, special patient groups, and strategies to enhance adherence and patient outcomes.